Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 3
1999 2
2000 6
2001 2
2002 4
2003 8
2004 7
2005 7
2006 5
2007 7
2008 7
2009 7
2010 5
2011 5
2012 3
2013 7
2014 6
2015 3
2016 1
2017 1
2018 5
2019 7
2020 3
2021 3
2022 2
2023 2
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis.
Andrews CP, Mohar D, Salhi Y, Tantry SK. Andrews CP, et al. Ann Allergy Asthma Immunol. 2020 Feb;124(2):171-178.e2. doi: 10.1016/j.anai.2019.11.007. Epub 2019 Nov 15. Ann Allergy Asthma Immunol. 2020. PMID: 31734334 Free article. Clinical Trial.
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate efficacy and safety of GSP301 in patients with seasonal AR (SAR). METHODS: In thi …
BACKGROUND: GSP301 is an investigational fixed-dose combination nasal spray of olopatadine hydrochloride (antihistamine) and m …
Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Dudeja L, Janakiraman A, Dudeja I, Sane K, Babu M. Dudeja L, et al. Indian J Ophthalmol. 2019 Sep;67(9):1400-1404. doi: 10.4103/ijo.IJO_2112_18. Indian J Ophthalmol. 2019. PMID: 31436181 Free PMC article. Clinical Trial.
There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. ...
There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic co …
Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
Butrus S, Greiner JV, Discepola M, Finegold I. Butrus S, et al. Clin Ther. 2000 Dec;22(12):1462-72. doi: 10.1016/s0149-2918(00)83044-1. Clin Ther. 2000. PMID: 11192137 Free article. Clinical Trial.
BACKGROUND: Mast cell stabilizers, such as the ocular antiallergic agent nedocromil sodium 2% ophthalmic solution, are not rapid acting and often require a loading period of > or =2 weeks for maximal efficacy. Olopatadine hydrochloride 0.1% ophthalmic solution is …
BACKGROUND: Mast cell stabilizers, such as the ocular antiallergic agent nedocromil sodium 2% ophthalmic solution, are not rapid acting and …
Pupil Diameter, Corneal Thickness, and Anterior Chamber Alterations Following Topical Olopatadine Hydrochloride 0.1%: A Single-Masked Randomized Controlled Clinical Study.
Çavdarli C, Topcu Yilmaz P. Çavdarli C, et al. J Ocul Pharmacol Ther. 2020 Sep;36(7):540-544. doi: 10.1089/jop.2020.0007. Epub 2020 Apr 3. J Ocul Pharmacol Ther. 2020. PMID: 32250190 Clinical Trial.
Purpose: Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. ...Conclusion: Olopatadine 0.1% does not lead to a significant change in corneal topography or anterior chamber parameters. ...
Purpose: Olopatadine hydrochloride 0.1% is one of the known primary topical treatments in ocular allergy. ...Conclusion: Ol …
Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.
Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Gross GN, et al. Ann Allergy Asthma Immunol. 2019 Jun;122(6):630-638.e3. doi: 10.1016/j.anai.2019.03.017. Epub 2019 Mar 22. Ann Allergy Asthma Immunol. 2019. PMID: 30910440 Free article. Clinical Trial.
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid). OBJECTIVE: To evaluate the efficacy and safety of GSP301 in patients with seasonal allergic rhinitis (SAR). METHODS: In t …
BACKGROUND: GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate …
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT, Abelson MB, Pasquine T, Stephens DM, Gamache DA, Gross RD, Robertson SM, Yanni JM. Vogelson CT, et al. Allergy Asthma Proc. 2004 Jan-Feb;25(1):69-75. Allergy Asthma Proc. 2004. PMID: 15055565 Clinical Trial.
Results of these preclinical experiments conducted in guinea pigs indicated that olopatadine 0.2% (wt/vol) solution was significantly effective 24 hours after dosing. This concentration of olopatadine provided significantly more efficacy than Patanol (olopatadine …
Results of these preclinical experiments conducted in guinea pigs indicated that olopatadine 0.2% (wt/vol) solution was significantly …
Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety.
Sil A, Tripathi SK, Chaudhuri A, Das NK, Hazra A, Bagchi C, Islam CN. Sil A, et al. J Dermatolog Treat. 2013 Dec;24(6):466-72. doi: 10.3109/09546634.2012.750414. Epub 2013 Feb 3. J Dermatolog Treat. 2013. PMID: 23163959 Free article. Clinical Trial.
Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety. RESULTS: Data from 54 subjects on olopatadine and 51 on levocetirizine were analyzed for effectiveness. UAS and TSS values declined significantly with both drugs ov …
Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety. RESULTS: Data from 54 subjects …
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ, Stoppel JO, Epstein AB. Berdy GJ, et al. Clin Ther. 2002 Jun;24(6):918-29. doi: 10.1016/s0149-2918(02)80007-8. Clin Ther. 2002. PMID: 12117082 Clinical Trial.
BACKGROUND: Olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension are topical antiallergic agents indicated for treatment of the signs and symptoms of allergic conjunctivitis and seasonal allergic conjunctivitis (SAC …
BACKGROUND: Olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension are topica …
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Borazan M, et al. Acta Ophthalmol. 2009 Aug;87(5):549-54. doi: 10.1111/j.1755-3768.2008.01265.x. Epub 2008 Jul 9. Acta Ophthalmol. 2009. PMID: 18631332 Free article. Clinical Trial.
PURPOSE: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC). ...A …
PURPOSE: We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emeda …
112 results